Overview

Efficacy and Safety of Oral NOMAC-E2 in Indian Women (P07057/MK-8175A-017)

Status:
Withdrawn

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

Summary

This study will investigate the efficacy and safety of the monophasic combined oral contraceptive (COC) containing 2.5 mg NOMAC and 1.5 mg E2 in healthy fertile Indian women.

Phase:

Phase 3

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Megestrol
Polyestradiol phosphate